In active IDU, Harvoni (Fixed dose combination ledipasvir/sofosbuvir), one pill orally daily x 12 weeks

In former IDU, Harvoni (Fixed dose combination ledipasvir/sofosbuvir), one pill orally daily x 12 weeks

HIV, HCV and HBV negative, never injected drugs, no recreational drugs for at least 2 years (does not include marijuana) and negative urine screen for opiates at the screening visit.

In active IDU, Harvoni (Fixed dose combination ledipasvir/sofosbuvir), one pill oral daily x 12 weeks.

Active Injection Drug Use (IDU)

In former IDU, Harvoni (Fixed dose combination ledipasvir/sofosbuvir), one pill oral daily x 12 weeks.

Former Injection Drug Use (Former IDU)

HIV, HCV, and HBV negative, never injected drugs, no recreational drugs for at least 2 years (does not include marijuana) and negative urine screen for opiates at screening.

Healthy Volunteers

Total

Sex: Female, Male

Region of Enrollment

Marker of immune activation as measured by levels of soluble CD14. Note that the levels of sCD14 were only measured at baseline in the Healthy Volunteers group and therefore there are no data for weeks 4, 12, or 24 entered.

In active IDU, Harvoni (Fixed dose combination ledipasvir/sofosbuvir), one pill orally daily x 12 weeks
Harvoni (Fixed dose combination ledipasvir/sofosbuvir): Harvoni (Fixed dose combination ledipasvir/sofosbuvir), one pill daily x 12 weeks

In former IDU, Harvoni (Fixed dose combination ledipasvir/sofosbuvir), one pill orally daily x 12 weeks
Harvoni (Fixed dose combination ledipasvir/sofosbuvir): Harvoni (Fixed dose combination ledipasvir/sofosbuvir), one pill daily x 12 weeks

sCD14 (ng/mL)

Virologic Response to Therapy as Measured by HCV RNA

Gene expression profiles in PBMC will be determined using RNA Seq

Gene Expression Profiles

Overall Study

Martin Markowitz MD

Hepatitis C

Harvoni (Fixed dose combination ledipasvir/sofosbuvir), one pill daily x 12 weeks

Harvoni (Fixed dose combination ledipasvir/sofosbuvir)

Rockefeller University Hospital

Immunologic Effects of HCV Therapy With HARVONI in HCV Genotype 1 Chronically Mono-infected Active and Former IDUs

The Immunologic Effects of HCV Therapy With Fixed Dose Combination Ledipasvir/Sofosbuvir (HARVONI) in HCV Genotype 1 Chronically Mono-infected Active and Former IDUs.

Martin Markowitz

Aaron Diamond Professor/Clinical Director

Rockefeller University

National Institute on Drug Abuse (NIDA)

The patients in the placebo group received equal numbers of identical looking placebo 2 h before operation

Patients in the gabapentin group received two capsules of gabapentin 300 mg (Neurontin®, Pfizer) at 2 h before operation.

Pruritus

Gabapentin

Songklanagarind Hospital

Gabapentin for Prophylaxis Intrathecal Morphine-Induced Pruritus

Gabapentin for Prophylaxis Intrathecal Morphine-Induced Pruritus After Orthopedics Surgery

the incidence of pruritus during the 24 h follow-up period

The difference of onset time and severity of pruritus in the gabapentin and placebo groups

anticonvulsants/viduriavimas

Immunologic Effects of HCV Therapy With HARVONI in HCV Genotype 1 Chronically Mono-infected Active and Former IDUs

Gabapentin for Prophylaxis Intrathecal Morphine-Induced Pruritus

Irinotecan in Treating Children With Refractory or Progressive Solid Tumors

Išsamiausia vaistinių žolelių duomenų bazė, paremta mokslu